Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

por Geynisman, Daniel M., Burotto, Mauricio, Porta, Camillo, Suarez, Cristina, Bourlon, Maria T., Huo, Stephen, Del Tejo, Viviana, Du, Ella X., Yang, Xiaoran, Betts, Keith A., Choueiri, Toni K., McGregor, Bradley
Publicado 2022

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma

por McGregor, Bradley, Geynisman, Daniel M, Burotto, Mauricio, Porta, Camillo, Suarez, Cristina, Bourlon, Maria T, Del Tejo, Viviana, Du, Ella X, Yang, Xiaoran, Sendhil, Selvam R, Betts, Keith A, Huo, Stephen
Publicado 2023

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

por Regan, Meredith M., Jegede, Opeyemi A., Mantia, Charlene M., Powles, Thomas, Werner, Lillian, Motzer, Robert J., Tannir, Nizar M., Lee, Chung-Han, Tomita, Yoshihiko, Voss, Martin H., Plimack, Elizabeth R., Choueiri, Toni K., Rini, Brian I., Hammers, Hans J., Escudier, Bernard, Albiges, Laurence, Huo, Stephen, Del Tejo, Viviana, Stwalley, Brian, Atkins, Michael B., McDermott, David F.
Publicado 2021